Checkpoint Therapeutics (NASDAQ:CKPT) Issues Earnings Results, Misses Expectations By $0.47 EPS

Checkpoint Therapeutics (NASDAQ:CKPT - Get Free Report) posted its earnings results on Friday. The company reported ($0.69) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.47), Zacks reports. The firm had revenue of $0.04 million for the quarter.

Checkpoint Therapeutics Stock Performance

Shares of CKPT stock remained flat at $4.04 during trading hours on Wednesday. 787,218 shares of the stock were exchanged, compared to its average volume of 1,129,505. Checkpoint Therapeutics has a 12 month low of $1.38 and a 12 month high of $4.50. The business has a fifty day moving average price of $3.38 and a two-hundred day moving average price of $3.30. The firm has a market cap of $197.29 million, a P/E ratio of -2.20 and a beta of 1.41.

Wall Street Analyst Weigh In

Several analysts have weighed in on the stock. Lake Street Capital reaffirmed a "hold" rating and set a $4.10 price objective (down from $7.00) on shares of Checkpoint Therapeutics in a research note on Monday, March 10th. D. Boral Capital restated a "buy" rating and set a $4.80 price target on shares of Checkpoint Therapeutics in a research report on Monday. Finally, HC Wainwright reiterated a "neutral" rating and issued a $4.10 price objective on shares of Checkpoint Therapeutics in a research report on Tuesday, March 11th.

Insider Activity at Checkpoint Therapeutics

In other Checkpoint Therapeutics news, CFO William Garrett Gray sold 74,110 shares of the business's stock in a transaction dated Thursday, February 6th. The stock was sold at an average price of $3.67, for a total transaction of $271,983.70. Following the completion of the sale, the chief financial officer now directly owns 1,458,644 shares of the company's stock, valued at approximately $5,353,223.48. The trade was a 4.84 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO James F. Oliviero III sold 9,233 shares of the firm's stock in a transaction dated Friday, February 7th. The shares were sold at an average price of $3.41, for a total transaction of $31,484.53. Following the completion of the transaction, the chief executive officer now directly owns 3,785,350 shares in the company, valued at $12,908,043.50. This trade represents a 0.24 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 93,674 shares of company stock valued at $336,011 over the last quarter. Corporate insiders own 2.10% of the company's stock.

About Checkpoint Therapeutics

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.